Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Value Unlocked: BMS Buying Padlock For Up To $600m

This article was originally published in Scrip

Executive Summary

Two years, $18m and a big pharma buyout for up to $600m? That's a great return for investors in Padlock Therapeutics Inc., a biotech firm that raised a single venture capital round in late 2014 to develop novel treatments for autoimmune diseases before Bristol-Myers Squibb Co. agreed to buy the company.

You may also be interested in...



Arrakis Pivots From Platform To Pipeline With $75m For RNA-Targeting Small Molecules

CEO Michael Gilman, who now helms the company full time, said Arrakis will use its Series B venture capital funding to build a pipeline of drug candidates, primarily in cancer, with the goal of taking its first medicines into the clinic in the next two to three years.

Start-Up Obsidian Gets $49.5m To Determine How And When To Activate CAR-T Cells

Obsidian CEO Michael Gilman described the company's technology – which allows CAR-T cells and other therapies to be activated by available small molecule drugs – as being able to modulate the effective yet toxic therapies by dialing down, turning up or shutting off the treatments as needed.

Finance Watch: Cash Flows Into Public Biopharmas, Including IPOs; Atlas Raises $350m VC Fund

Public biopharma offerings gained momentum, including four IPOs during the last week of June, as US investors looked kindly on the sector ahead of July 4 celebrations. Also, VC investment continued unabated as Atlas Venture closed a new $350m fund.

Related Content

Topics

UsernamePublicRestriction

Register

SC064818

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel